Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC, McFadyen L, Watson KJ, Riccobene T, Carrothers TJ, Vourvahis M, Chan PLS, Raber S, Bradley JS, Lovern M. Franzese RC, et al. Among authors: mcfadyen l. Clin Pharmacol Ther. 2022 Mar;111(3):635-645. doi: 10.1002/cpt.2460. Epub 2021 Nov 22. Clin Pharmacol Ther. 2022. PMID: 34687548 Free PMC article. Clinical Trial.
The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
Chan PLS, McFadyen L, Quaye A, Leister-Tebbe H, Hendrick VM, Hammond J, Raber S. Chan PLS, et al. Among authors: mcfadyen l. CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):551-563. doi: 10.1002/psp4.12608. Epub 2021 May 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33687148 Free PMC article.
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. Vourvahis M, et al. Among authors: mcfadyen l. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. J Clin Pharmacol. 2019. PMID: 30192390 Free PMC article. Clinical Trial.
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Liyanage M, Nikanjam M, McFadyen L, Vourvahis M, Rogg L, Moye J, Chadwick EG, Jean-Philippe P, Mirochnick M, Whitson K, Bradford S, Capparelli EV, Best BM. Liyanage M, et al. Among authors: mcfadyen l. Pediatr Infect Dis J. 2022 Nov 1;41(11):885-890. doi: 10.1097/INF.0000000000003665. Epub 2022 Aug 9. Pediatr Infect Dis J. 2022. PMID: 35980827 Free PMC article.
Pharmacokinetics and safety of maraviroc in neonates.
Rosebush JC, Best BM, Chadwick EG, Butler K, Moye J, Smith E, Bradford S, Reding CA, Mathiba SR, Hanley S, Aziz M, Homans J, Acosta EP, Murtaugh W, Vourvahis M, Mcfadyen L, Hayward K, Mirochnick M, Samson P; for the IMPAACT 2007 Study Team. Rosebush JC, et al. Among authors: mcfadyen l. AIDS. 2021 Mar 1;35(3):419-427. doi: 10.1097/QAD.0000000000002762. AIDS. 2021. PMID: 33252481 Free PMC article.
47 results